Jin Rong Jie·2025-08-11 02:24Core Viewpoint - China National Pharmaceutical Group (01177) experienced a decline of 4.48% in stock price, trading at 7.03 CNY per share with a transaction volume of 303 million CNY as of 10:10 AM on August 11 [1] Group 1: Company Overview - China National Pharmaceutical Group is an innovative research and development-driven pharmaceutical company, focusing on drug research, intelligent manufacturing, and sales [1] - The company specializes in various biological and chemical drugs, particularly excelling in four therapeutic areas: oncology, liver diseases, respiratory systems, and surgical/pain management [1] - Since its listing in 2000, the company has been included in multiple indices such as the MSCI Global Standard Index and the Hang Seng Index, and has been recognized in the "Top 50 Global Pharmaceutical Companies" by Pharmaceutical Manager for six consecutive years [1] Group 2: Financial Performance - As of the 2024 annual report, China National Pharmaceutical Group reported total revenue of 28.866 billion CNY and a net profit of 3.5 billion CNY [1] - The revenue contribution from the company's products has been increasing year by year [1] Group 3: Upcoming Events - The company is set to disclose its mid-year report for the fiscal year 2025 on August 18 [1]